23:44 , Mar 9, 2018 |  BC Extra  |  Company News

Coherus gains on plans to resubmit BLA for Neulasta biosimilar

Coherus BioSciences Inc. (NASDAQ:CHRS) rose $2.75 (30%) to $11.85 on Friday after announcing in its earnings that it will resubmit a BLA for CHS-1701, with plans to launch the product in the U.S. next half....
20:40 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

Daiichi ends Japanese development of Coherus' Enbrel biosimilar

Daiichi Sankyo Co. Ltd. (Tokyo:4568) discontinued development in Japan of CHS-0214 (BAX 2200), a biosimilar of Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN), to treat rheumatoid arthritis. Coherus BioSciences Inc. (NASDAQ:CHRS) said it regained territorial rights...
20:30 , Jul 5, 2017 |  BC Extra  |  Company News

Daiichi ends development of Coherus' biosimilar of Enbrel

Coherus Biosciences Inc. (NASDAQ:CHRS) slipped $0.25 to $14.40 on Wednesday after partner Daiichi Sankyo Co. Ltd. (Tokyo:4568) discontinued development in Japan of CHS-0214, a biosimilar of Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN), to treat rheumatoid...
00:42 , Dec 21, 2016 |  BC Week In Review  |  Clinical News

Lifmior regulatory update

EMA’s CHMP recommended approval of Pfizer’s Lifmior etanercept, a product identical to Enbrel, to treat rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis and pediatric plaque psoriasis. Pfizer has rights to...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

Brenzys biosimilar etanercept regulatory update

Samsung Bioepis Co. Ltd. and Merck said Canada approved Brenzys etanercept, a biosimilar of autoimmune drug Enbrel etanercept, to treat rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Merck will commercialize the biosimilar in Canada....
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Erelzi etanercept-szzs regulatory update

FDA approved a BLA from Novartis’ Sandoz unit for Erelzi etanercept-szzs, a biosimilar of autoimmune drug Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). Erelzi is approved in all indications included on...
07:00 , Jul 25, 2016 |  BioCentury  |  Strategy

Paving the way

Amgen Inc. and the Sandoz unit of Novartis AG are charting a course that could create competitive U.S. markets for two of the biggest prizes in the biosimilars universe, AbbVie Inc.'s Humira adalimumab and Amgen's...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

Biosimilar etanercept: Phase III data

Top-line data from the double-blind, international Phase III EGALITY trial in 531 patients with moderate to severe chronic plaque-type psoriasis showed that GP2015 met the primary endpoint of equivalence to Enbrel etanercept as measured...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

Biosimilar etanercept regulatory update

FDA’s Arthritis Advisory Committee voted unanimously to recommend approval of GP2015, a biosimilar of autoimmune drug Enbrel etanercept, from the Sandoz unit of Novartis. The advisory committee supported Sandoz’s request for approval in all...